World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 December 2018
Melanoma Institute Australia (MIA) is proud to have one of the world’s leading pathologists, Associate Professor Michael Tetzlaff, with us for this past week.
A/Prof Tetzlaff hails from the Department of Pathology and Translational and Molecular Pathology at the MD Anderson Cancer Centre at The University of Texas.
Spending his time with fellow pathologist Professor Richard Scolyer, MIA’s Co-Medical Director, and his team at Royal Prince Alfred Hospital, A/Prof Tetzlaff is sharing his pathological expertise in primary mucosal melanoma and merkel cell carcinoma, and assisting in the assessment of pathological samples from patients undergoing neoadjuvant, targeted therapy.
Among over 100 published peer-reviewed articles, A/Prof Tetzlaff is also lead author on a paper recently published by the International Neoadjuvant Melanoma Consortium that aims to standardise the pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy.
It is an honour to have Associate Professor Tetzlaff as an international collaborator, and we are delighted to be hosting him on his first ever trip to Australia.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.